Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated by Analysts at Stifel Nicolaus

Equities researchers at Stifel Nicolaus initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research note issued on Thursday,Benzinga reports. The firm set a “buy” rating and a $25.00 price target on the stock. Stifel Nicolaus’ price target suggests a potential upside of 292.46% from the company’s current price.

EPRX has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st. Zacks Research raised shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. William Blair initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They issued an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Finally, Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eupraxia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $18.33.

Eupraxia Pharmaceuticals Price Performance

NASDAQ:EPRX opened at $6.37 on Thursday. Eupraxia Pharmaceuticals has a one year low of $3.67 and a one year high of $9.32. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The firm has a market cap of $384.94 million, a price-to-earnings ratio of -6.07 and a beta of 1.19. The firm’s fifty day moving average is $7.20 and its two-hundred day moving average is $7.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Research analysts expect that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in EPRX. Vivo Capital LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the third quarter worth $7,965,000. Affinity Asset Advisors LLC grew its stake in shares of Eupraxia Pharmaceuticals by 429.7% during the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after purchasing an additional 1,289,005 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the third quarter worth $5,398,000. Redmile Group LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the first quarter worth $5,068,000. Finally, Rubric Capital Management LP acquired a new position in shares of Eupraxia Pharmaceuticals during the first quarter worth $5,004,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.